Cara Therapeutics

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Cara Therapeutics reports solid Q4 earnings amidst growth opportunities

Cara Therapeutics showcased strong revenue growth and positive feedback on KORSUVA injection sales in Q4 2022.
While facing challenges such as demand instability and regulatory uncertainties, the company remains confident in its growth prospects.
Strategic investments, milestone anticipation, and financial stability position Cara well for future value creation and market expansion.

Cara Therapeutics reports strong Q1 revenue, optimistic about pipeline growth

Cara Therapeutics delivered solid revenue in Q1 2023 driven by the successful launch of KORSUVA and Kapruvia. While facing increased operating expenses, the company remains optimistic about its pipeline's potential. Strategic focus on KORSUVA's success and ongoing R&D efforts position Cara for future growth.

Cara Therapeutics reports solid Q2 earnings amidst regulatory uncertainties

Cara Therapeutics posted strong financial performance in Q2 2023, driven by robust net sales and cash reserves, with a focus on maximizing shareholder value.
The company faces challenges related to potential CMS changes and European market dynamics but sees opportunities in international expansion and regulatory engagement.
Overall, Cara Therapeutics remains optimistic about the commercial prospects of its key products and pipeline, aiming for sustained growth and market leadership.

Cara Therapeutics extends cash runway, faces funding challenges ahead

Cara Therapeutics reports strong financials with extended cash runway. Progress in late-stage programs and successful monetization of royalties. Facing challenges with funding limitations and uncertainties around data releases.

Cara Therapeutics extends cash runway to 2026 amidst revenue challenges

Cara Therapeutics strategically focused on NP and oral DSK programs to drive growth.
Strong demand for KORSUVA injection but challenges from reimbursement changes.
Confidence in NP program and potential partnerships signal future opportunities.
Financially extended runway to 2026 but facing liquidity challenges with $1.8 million cash.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– 4Q22 total revenue was $3.3 million including collaborative revenue of $1.1 million from the Company's share of profit of KORSUVA ® (difelikefalin) injection; FY22 revenue was $41.9 million including collaborative revenue of $16.6 million –

Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Cara Therapeutics (CARA) Report Negative Earnings Next Week? What You Should Know

STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, March 6, 2023, at 4:30 p.m. EST to report fourth quarter and full year 2022 financial results and provide a corporate update.

Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

Publication underscores the importance of data in underrecognized neuropathic itch disorder which lacks an approved treatment Publication underscores the importance of data in underrecognized neuropathic itch disorder which lacks an approved treatment

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine

STAMFORD, Conn., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host an in-person and virtual Capital Markets Day in New York City on Thursday, February 16, 2023, from 10:00 a.m. to 1:00 p.m. EST.

Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023

STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 11:15 a.m. PST (2:15 p.m. EST) in San Francisco, CA.

Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

Aurora Cannabis

AFC Gamma

Beyond Meat

Canopy Growth

Amplify Seymour Cannabis ETF

Cronos Group

Curaleaf Holdings, Inc.

Direxion Daily CSI China Internet Index Bull 2X Shares

Flora Growth Corp

GrowGeneration Corp

Green Thumb Industries Inc.

GW Pharmaceuticals

High Tide

Hydrofarm Holdings Group

Innovative Industrial Properties

Intercure Ltd

Amplify Alternative Harvest ETF

Cannabis REITs have been slammed this year amid concern over defaults from their cannabis cultivator tenants, which have been smoked by plunging wholesale cannabis prices and setbacks on federal legalization. The exclusion of the SAFE Banking Act from the omnibus federal spending package dimmed the once-high hopes that major federal marijuana legislation would be passed during the Biden Presidency.

Cannabis REITs: Smoked Out

Fintel reports that Bain Capital Life Sciences Opportunities III, LP has filed a 13G form with the SEC disclosing ownership of 2,696,030 shares of Cara Therapeutics Inc (CARA).

Bain Capital Life Sciences Discloses Position in CARA / Cara Therapeutics

Cara Therapeutics, Inc. (NASDAQ:CARA ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Matthew Murphy - Manager, Investor Relations Christopher Posner - President, CEO & Director Ryan Maynard - CFO Joana Goncalves - Chief Medical Officer Conference Call Participants Sumant Kulkarni - Canaccord Genuity Joseph Stringer - Needham & Company Daniel Wolle - JPMorgan Chase & Co. Chi Meng Fong - Bank of America Merrill Lynch Stacy Lee - Stifel David Amsellem - Piper Sandler & Co. Operator Good afternoon. My name is Shannon, and I will be your conference facilitator.

Cara Therapeutics, Inc. (CARA) Q3 2022 Earnings Call Transcript

Cara (CARA) delivered earnings and revenue surprises of -2.38% and 28.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates

– Net revenue was $16.2M for 3Q22 including profit-sharing revenue of $7.4M from KORSUVA ® (difelikefalin) injection –

Cara Therapeutics Reports Third Quarter 2022 Financial Results

Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Cara Therapeutics (CARA) Might Surprise This Earnings Season

STAMFORD, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that members of its Executive Leadership Team will present at the following investor conferences:

Cara Therapeutics to Present at Upcoming Investor Conferences

Cara (CARA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cara Therapeutics (CARA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

STAMFORD, Conn., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, November 7, 2022, at 4:30 p.m. ET to report third quarter 2022 financial results and provide a corporate update.

Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022

The mean of analysts' price targets for Cara (CARA) points to a 132.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 133% Upside in Cara (CARA): Can the Stock Really Move This High?

Milestone payment highlights ongoing clinical progress of Oral KORSUVA™ DALLAS , Oct. 10 2022  /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned subsidiary, Enteris BioPharma, received a $5 million clinical progression milestone payment from Cara Therapeutics (Nasdaq: CARA) related to the license agreement for the Peptelligence® oral formulation technology utilized in Oral KORSUVA™, the oral formulation of Cara's first-in-class KOR agonist, CR845/difelikefalin. Enteris is entitled to retain $2.5 million of this payment per the contractual splits agreed to in the Enteris acquisition agreement.

SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics

STAMFORD, Conn., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd. submitted a New Drug Application (NDA) in Japan for approval of difelikefalin for the treatment of pruritus in hemodialysis patients.

Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations.

Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) –

Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

STAMFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022, at 8:30 a.m. ET.

Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Korsuva has been approved in an indication for which, it faces little in the way of competition. A number of expansion opportunities await oral difelikefalin, with positive phase 2 data for NP opening the door to additional indications.

Cara Therapeutics: All Eyes On Korsuva Launch Metrics

Presentation will highlight opportunity for oral difelikefalin to address a significant unmet need in the treatment of pruritus in patients with NP Presentation will highlight opportunity for oral difelikefalin to address a significant unmet need in the treatment of pruritus in patients with NP

Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022

Oral presentation will include data from the Phase 2 trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica Oral presentation will include data from the Phase 2 trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica

Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress

ST. GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by

News for Cara Therapeutics Stock (CARA)